Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 April 2021 | Story Nonsindiso Qwabe | Photo Sonia SMall

How has COVID-19 further widened the gender inequality gap in the workplace?

This was the central question addressed during the first instalment of a webinar series on Gender and Social Justice hosted by the Unit for Institutional Change and Social Justice at the University of the Free State (UFS). The webinar, which was hosted on the UFS Qwaqwa Campus on 29 March 2021, featured Prof Pearl Sithole, Qwaqwa Campus Vice-Principal: Academic and Research; Advocate Nthabiseng Sepanya-Mogale, Commissioner at the Commission for Gender Equality (CGE); and Tholo Motaung, skills trainer, moderator, and gender activist at the Vaal University of Technology as panellists. 

Prof Sithole said COVID-19 revealed the disparity that still exists between men and women in the workplace. “COVID-19 has been the magnifier. We’ve modernised quite a lot, but we’re still unequal in terms of gender. Why are we not progressing in terms of women moving forward towards equality when there has been so much progressive thinking in the political space, social justice space, as well as in the kind of feminism we have had in academia? Why are we actually not winning the battle of just regarding each other as equals?” 

Women hardest hit by COVID-19 lockdown

Advocate Sepanya-Mogale said the lockdown revealed the gender gap mostly through the significant impact it has had on South African women.

In 2020, 34% of the country’s workforce comprised women – a sharp decline of 9,8% from 43,8% in 2018.
“This decline is alarming and a clear indication of who becomes the first victims, but that is hardly talked about. A lot of women have experienced resistance from industries they had been serving diligently,” she said. She said women were often faced with the burden of integrating their work with increased care responsibilities for their children and sometimes also the elderly as primary caregivers. The double responsibility placed on women continues to re-enforce gender roles in our societies and further pushes away the success of closing the gap on gender equality prospects in our society.

Advocate Sepanya-Mogale said women were the hardest hit in most industries. In the beauty and tourism industry; air transportation; informal trading; and healthcare sector to name a few, women bore the brunt the most. “Women are the biggest employees on all economic levels in South Africa, especially the low-income and unskilled levels,” she said.
She said as the spread of the virus was likely to continue disrupting economic activity, all sectors of society needed to get involved and play their part.

“As disease outbreaks are not likely to disappear in the near future, proactive international action is required to not only save lives but to also protect economic prosperity. Academic institutions are authorities in terms of opening up new discussions, leading new debates, and putting critical issues at the centre of the table. Let us all do what we can so that we empower our people relevantly for the times we’re living in.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept